Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anisha B Patel

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Dermatology Online Journal|August 13, 2021
Disseminated atypical mycobacterial infection in an allogeneic stem cell transplant recipientPadmavathi V Karri, Carlos A Torres, Natalie Jm Dailey Garnes, et al.
Journal for Immunotherapy of Cancer|August 8, 2025
Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitorsOmar Pacha, Anisha B Patel, Jonathan L Curry, et al.
Journal of the American Academy of Dermatology|March 11, 2018
Surgical site identification with personal digital device: A prospective pilot studyLeon Chen, Adam M Parsons, Alexander B Aria, et al.
Cancer Immunology Research|April 19, 2019
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from ImmunotherapyDaniel Johnson, Anisha B Patel, Marc I Uemura, et al.
Cancer Discovery|April 29, 2021
Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor TherapyMario E Lacouture, Zev A Wainberg, Anisha B Patel, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
IGF1 modulates lesional skin inflammation in checkpoint inhibitor-induced lichen planusNoah I Hornick, Avery Billo, Rosalyn M Fey, et al.
Cancer|January 21, 2026
Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 alleleMckenzie DiLeo, Samantha Oglesby, Cheuk Hong Leung, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 21, 2025
Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidanceKim A Papp, Luis Puig, Jennifer Beecker, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2024
Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse EventsSarah E Fayle, Nicolas L Palaskas, Bilal A Siddiqui, et al.
Journal of Cutaneous Pathology|December 10, 2021
Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinomaRiyad N H Seervai, Meghan Heberton, Woo Cheal Cho, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Dermatology Online Journal|August 13, 2021
Disseminated atypical mycobacterial infection in an allogeneic stem cell transplant recipientPadmavathi V Karri, Carlos A Torres, Natalie Jm Dailey Garnes, et al.
Journal for Immunotherapy of Cancer|August 8, 2025
Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitorsOmar Pacha, Anisha B Patel, Jonathan L Curry, et al.
Journal of the American Academy of Dermatology|March 11, 2018
Surgical site identification with personal digital device: A prospective pilot studyLeon Chen, Adam M Parsons, Alexander B Aria, et al.
Cancer Immunology Research|April 19, 2019
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from ImmunotherapyDaniel Johnson, Anisha B Patel, Marc I Uemura, et al.
Cancer Discovery|April 29, 2021
Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor TherapyMario E Lacouture, Zev A Wainberg, Anisha B Patel, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
IGF1 modulates lesional skin inflammation in checkpoint inhibitor-induced lichen planusNoah I Hornick, Avery Billo, Rosalyn M Fey, et al.
Cancer|January 21, 2026
Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 alleleMckenzie DiLeo, Samantha Oglesby, Cheuk Hong Leung, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 21, 2025
Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidanceKim A Papp, Luis Puig, Jennifer Beecker, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2024
Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse EventsSarah E Fayle, Nicolas L Palaskas, Bilal A Siddiqui, et al.
Journal of Cutaneous Pathology|December 10, 2021
Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinomaRiyad N H Seervai, Meghan Heberton, Woo Cheal Cho, et al.
Pageof 9